3. Program Goals

5. Teriflunomide: Pooled Safety Data

6. Alemtuzumab: Thyroid Adverse Events

7. Alemtuzumab: Efficacy

8. Alfacalcidol (Vitamin D Analogue) for Managing MS-Related Fatigue

9. Thalamic Atrophy in RIS

10. Fingolimod and Brain Volume Change

11. Contraceptives and MS Susceptibility

12. Smoking and MS

13. Smoking and MS (cont)

14. MS Performance Testing

15. Driving Assessment

16. Cognitive Impairment in Pediatric Patients With MS

17. Pegylated Interferon: ADVANCE Study

18. Outcome Measures: Disease Worsening

19. Outcome Measures: Disease Worsening (cont)

20. Natalizumab: STRATA Study

21. Impact of Relapse Recovery on Progressive Disease

22. Risk Factors

23. Ofatumumab: MIRROR Study

24. Summary and Key Points

25. Abbreviations

26. References

27. References (cont)

28. References (cont)

29. References (cont)

30. References (cont)